New injection aims to ease knee arthritis pain and protect cartilage

NCT ID NCT05462990

Terminated Symptom relief Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested an investigational drug called QUC398 in 101 people with painful knee osteoarthritis. Participants received either QUC398 injections or a placebo. The goal was to see if the drug could reduce knee pain and improve cartilage health. The trial was terminated early, so final conclusions are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: QUC398 (injectable drug)
What this could lead to: If successful, QUC398 could offer a new option to reduce knee pain and potentially slow cartilage loss in osteoarthritis.
What could go wrong: This was an early proof-of-concept study that was terminated, so results are limited. The drug may not prove effective or safe in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOARTHRITIS, KNEE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

osteoarthritis osteoarthritis, knee

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OSTEOARTHRITIS, KNEE

Contacts and locations

Locations

Boston Univ School of Medicine

Boston, Massachusetts, 02118, United States
Clinical Research of West Florida Inc

Tampa, Florida, 33603, United States
Novartis Investigative Site

Southport, Queensland, 4222, Australia
Novartis Investigative Site

Christchurch, 8011, Australia
Novartis Investigative Site

St Leonards, 2065, Australia
Novartis Investigative Site

Herlev, 2730, Denmark
Novartis Investigative Site

Vejle, 7100, Denmark
Novartis Investigative Site

Nice, 06001, France
Novartis Investigative Site

Orléans, 45100, France
Novartis Investigative Site

Sabadell, Barcelona, 08208, Spain
Novartis Investigative Site

Leganés, Madrid, 28915, Spain
Novartis Investigative Site

A Coruña, 15006, Spain
Novartis Investigative Site

Seville, 41010, Spain
West Clinical Research

Morehead City, North Carolina, 28557, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.